{"nctId":"NCT03176771","briefTitle":"Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia","startDateStruct":{"date":"2017-06-21","type":"ACTUAL"},"conditions":["Tardive Dyskinesia"],"count":256,"armGroups":[{"label":"MT-5199 40 mg (Double-Blind Placebo-Controlled Period)","type":"EXPERIMENTAL","interventionNames":["Drug: MT-5199","Drug: Placebo"]},{"label":"MT-5199 80 mg (Double-Blind Placebo-Controlled Period)","type":"EXPERIMENTAL","interventionNames":["Drug: MT-5199","Drug: Placebo"]},{"label":"Placebo (Double-Blind Placebo-Controlled Period)","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo"]},{"label":"MT-5199 40 mg (Double-Blind Extension Period)","type":"EXPERIMENTAL","interventionNames":["Drug: MT-5199","Drug: Placebo"]},{"label":"MT-5199 80 mg (Double-Blind Extension Period)","type":"EXPERIMENTAL","interventionNames":["Drug: MT-5199","Drug: Placebo"]}],"interventions":[{"name":"MT-5199","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have one of the following clinical diagnoses for at least 3 months prior to screening: Schizophrenia or Schizoaffective Disorder, Bipolar Disorder, or Depressive Disorders.\n* Have a clinical diagnosis of neuroleptic-induced TD.\n* Have moderate or severe TD.\n* If using maintenance medication(s) for schizophrenia or schizoaffective disorder, or bipolar disorder, or depressive disorders, be on stable doses.\n\nExclusion Criteria:\n\n* Have an active, clinically significant unstable medical condition in screening period.\n* Have a significant risk of suicidal or violent behavior.\n* Have a known history of long QT syndrome or cardiac tachy-arrhythmia.\n* Are currently pregnant or breastfeeding.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Central Assessment) at Week 6","description":"Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded central AIMS raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":null},{"groupId":"OG001","value":"-2.3","spread":null},{"groupId":"OG002","value":"-3.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With a â‰¥50% Improvement From Baseline in the AIMS Total Score (Central Assessment) at Week 6 (AIMS Responder)","description":"Percentage of AIMS responders (subjects who had at least a 50 percent reduction in AIMS score from baseline)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":null},{"groupId":"OG001","value":"23.9","spread":null},{"groupId":"OG002","value":"47.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Site Assessment) at Week 6","description":"Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded site AIMS raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":null},{"groupId":"OG001","value":"-3.8","spread":null},{"groupId":"OG002","value":"-4.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression of Change - TD (CGI-TD) Score at Week 6","description":"Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"3.0","spread":null},{"groupId":"OG002","value":"2.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":84},"commonTop":["Nasopharyngitis","Somnolence","Schizophrenia","Salivary hypersecretion","Insomnia"]}}}